REQUEST A DEMO
Total
USD $0.00
Search more companies

Cellid Co.,Ltd. (South Korea)

Main Activities: Biological Product (except Diagnostic) Manufacturing
Full name: Cellid Co.,Ltd. Profile Updated: July 08, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

The Company is a Korea-based company mainly engaged in the research and development of cancer therapeutic vaccine. The Company develops cancer therapeutic vaccine through development and clinical research of BVAC pipeline products using CeliVax original technology. The Company was established on December 01, 2006. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on February 20, 2019.

Headquarters
5F, 142-Dong, College Of Pharmacy, Seoul Univ., 1, Gwanak-Ro, Gwanak-Gu
Seoul; Seoul;

Contact Details: Purchase the Cellid Co.,Ltd. report to view the information.

Website: http://www.cellid.co.kr

Basic Information
Total Employees:
Purchase the Cellid Co.,Ltd. report to view the information.
Outstanding Shares:
Purchase the Cellid Co.,Ltd. report to view the information.
Registered Capital:
Purchase the Cellid Co.,Ltd. report to view the information.
Financial Auditors:
Purchase the Cellid Co.,Ltd. report to view the information.
Incorporation Date:
December 11, 2006
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Ownership Details
Purchase this report to view the information.
19.4%
Purchase this report to view the information.
12.6%
Purchase this report to view the information.
2%
Subsidiaries
(주)셀리드
Company Performance
Financial values in the chart are available after Cellid Co.,Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Total operating revenue
95.62%
Operating profit (EBIT)
-59.1%
EBITDA
-93.73%
Net Profit (Loss) for the Period
25.28%
Total assets
39.39%
Total equity
80.47%
Return on Equity (ROE)
40.58%
Debt to Equity Ratio
-23.54%
Quick Ratio
0.61%
Cash Ratio
0.89%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?